Apogee Therapeutics, Inc.

NasdaqGM APGE

Apogee Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -133.21 M

Apogee Therapeutics, Inc. Operating Cash Flow is USD -133.21 M for the Trailing 12 Months (TTM) ending September 30, 2024. Operating cash flow is cash generated from the company’s regular business operations.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
NasdaqGM: APGE

Apogee Therapeutics, Inc.

CEO Dr. Michael Thomas Henderson M.D.
IPO Date July 14, 2023
Location United States
Headquarters 221 Crescent Street
Employees 91
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

StockViz Staff

January 15, 2025

Any question? Send us an email